HEAD AND NECK SQUAMOUS CELL CARCINOMA

This early-phase trial is testing a new drug called OKN4395, which blocks certain inflammatory signals, both alone and combined with the immunotherapy pembrolizumab. The study will enroll about 146 people with advanced solid tumors (including lung, colorectal, and stomach cancers…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Epkin • Aim: Disease control

Last updated Jun 23, 2026 16:46 UTC

New antibody combo takes on Hard-to-Treat cancers

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Zumutor Biologics Inc. • Aim: Disease control

Last updated Jun 23, 2026 11:56 UTC

New experimental drug CTX-8371 enters first human tests for tough cancers

This early-stage study is testing an experimental drug called CTX-8371 in people with advanced lung, breast, lymphoma, head and neck, or skin cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 parti…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Compass Therapeutics • Aim: Disease control

Last updated Jun 23, 2026 11:55 UTC

New cancer drug SIM0610 enters first human tests

This early-phase trial is testing an experimental drug called SIM0610 in 260 adults with advanced solid tumors, including lung, colorectal, head and neck, and liver cancers. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Particip…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 23, 2026 11:55 UTC

New CAR T-Cell therapy takes on Hard-to-Treat cancers

This early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control

Last updated Jun 22, 2026 12:09 UTC

New pill takes on tough cancers: early trial launches

This study tests a new daily pill, VLS-1488, for people with advanced solid tumors that have not responded to other treatments. About 200 participants with specific cancers like ovarian, lung, or breast cancer will receive the drug to see if it is safe and shrinks tumors. The goa…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Volastra Therapeutics, Inc. • Aim: Disease control

Last updated Jun 22, 2026 12:08 UTC

New drug targets Hard-to-Treat cancers with genetic weakness

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control

Last updated Jun 22, 2026 12:07 UTC

New drug BL-B01D1 targets Hard-to-Treat cancers in early trial

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control

Last updated Jun 22, 2026 12:07 UTC

New drug ALE.P02 targets tough cancers in early trial

This study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus that have spread or cannot be removed. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 170 adult…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control

Last updated Jun 22, 2026 12:05 UTC

New hope for head and neck cancer: cetuximab after failed immunotherapy

This study is for people with head and neck cancer that has come back or spread. It tests whether the drug cetuximab, given alone, can shrink tumors in patients who no longer respond to or cannot tolerate immunotherapy. About 38 adults will receive cetuximab and be monitored for …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control

Last updated Jun 22, 2026 12:03 UTC

New drug EPI-326 enters first human tests for tough cancers

This early-phase study tests a new drug called EPI-326 in people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to check safety and find the best dose. About 110 participants will take part.

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control

Last updated Jun 22, 2026 12:03 UTC

New drug duo targets Hard-to-Treat head and neck cancer

This phase II trial tests a new drug called SIBP-03, given together with cetuximab, for people with advanced head and neck cancer that has returned or spread. The study will enroll 81 adults who have already tried immunotherapy and platinum chemotherapy. The goal is to see if the…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Shanghai Institute Of Biological Products • Aim: Disease control

Last updated Jun 22, 2026 12:01 UTC

New Antibody-Drug conjugate targets Hard-to-Treat cancers

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control

Last updated Jun 22, 2026 12:00 UTC

Experimental cocktail aims to tackle recurrent head and neck cancer

This early-phase trial is testing a combination of two newer drugs (tislelizumab and pamiparib) plus standard chemotherapy and a second round of radiation in people whose head and neck cancer has come back. The main goal is to find the safest dose of pamiparib when used in this m…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control

Last updated Jun 22, 2026 11:59 UTC

Cancer-Killing virus trial launches for patients out of options

This early-phase trial is testing a new treatment called VET3-TGI, a virus engineered to attack cancer cells. It is given alone or with the immunotherapy drug atezolizumab to up to 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control

Last updated Jun 22, 2026 11:59 UTC

Could a Sugar-Blocking pill boost immunotherapy for tough cancers?

This phase 2 trial tests whether adding an experimental drug called GB1211 to the immunotherapy Keytruda works better than Keytruda alone for people with advanced melanoma or head & neck cancer. GB1211 blocks a protein called galectin-3, which may help tumors hide from the immune…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control

Last updated Jun 22, 2026 11:56 UTC

Blood test guides chemo timing in head and neck cancer trial

This phase 2 study tests whether adding occasional chemotherapy to the immunotherapy drug pembrolizumab (Keytruda) can improve outcomes for people with recurrent or metastatic head and neck cancer. A blood test that measures tumor DNA helps doctors decide when to give the chemo. …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control

Last updated Jun 22, 2026 11:56 UTC

New drug cocktail aims to shrink head and neck tumors before surgery

This phase 2 trial is testing whether giving two drugs—pembrolizumab (Keytruda) and IO102-103—before surgery is safe and effective for people with head and neck cancer. The study will enroll 30 adults whose cancer can be surgically removed. Researchers will watch for side effects…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control

Last updated Jun 22, 2026 11:56 UTC

New drug IDE034 targets Hard-to-Treat cancers in early trial

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control

Last updated Jun 18, 2026 11:50 UTC

New drug combo targets Hard-to-Treat cancers in early trial

This study tests an experimental oral drug, VMD-928, given alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shrink tumors. Ab…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: VM Oncology, LLC • Aim: Disease control

Last updated Jun 18, 2026 11:50 UTC

Promising new combo targets advanced head and neck cancer

This study tests a new combination of drugs (SI-B001 and SI-B003) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if this combo can shrink tumors and slow the disease. About 60 adults aged 18 to 75 will …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 18, 2026 11:49 UTC

New injection attacks tumors from inside

This early-phase trial tests an experimental drug, ONM-501, injected directly into tumors. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The study aims to find the safest dose and see if combining it with another drug (cemip…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: OncoNano Medicine, Inc. • Aim: Disease control

Last updated Jun 18, 2026 11:47 UTC

New vaccine combo aims to wipe out head and neck tumors before surgery

This study tests a new treatment for people with a type of head and neck cancer that has not spread too far. The treatment combines an experimental vaccine (IMP3-Mito) with immunotherapy drugs, given before and after surgery. The goal is to shrink the tumor more effectively and l…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control

Last updated Jun 18, 2026 11:46 UTC

Could low-dose radiation boost cancer treatment before surgery?

This study compares two treatment approaches for people with operable head and neck squamous cell carcinoma. One group receives low-dose radiotherapy plus targeted therapy and immunotherapy before surgery, while the other gets only targeted therapy and immunotherapy. The goal is …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control

Last updated Jun 17, 2026 12:09 UTC

Can a gene test guide better treatment for head and neck cancer survivors?

This study compares two treatments after surgery for stage III-IVA head and neck cancer: radiation alone versus radiation plus the chemotherapy drug cisplatin. The goal is to see which approach better prevents the cancer from returning, especially in patients with certain TP53 ge…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control

Last updated Jun 17, 2026 12:08 UTC

Could a drug combo before surgery eliminate the need for radiation in head and neck cancer?

This study is for people with a type of head and neck cancer that can be removed with surgery. Researchers want to see if adding two immunotherapy drugs (cemiplimab and cetuximab) to standard chemotherapy before surgery is safe and might allow patients to skip radiation after sur…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Jun 17, 2026 12:08 UTC

New drug targets 'Undruggable' cancer mutation in early trial

This early-phase study tests a new drug, CLSP-1025, designed to attack cancer cells that have a specific change in the p53 gene (called R175H). The study enrolls adults with advanced solid tumors (like lung, colon, or breast cancer) that have this mutation and a specific immune t…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control

Last updated Jun 17, 2026 12:06 UTC

Engineered immune cells take aim at Hard-to-Treat cancers

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jun 17, 2026 12:06 UTC

New drug duo takes on hard-to-treat head and neck cancers

This study tests two experimental drugs, BL-B01D1 and SI-B003, given alone or together, in people with head and neck cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or slow the disease. About 186 adults aged 18 to 75 who have tried at…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 17, 2026 12:05 UTC

New antibody drug enters first human tests for hard-to-treat cancers

This early-phase study tests a new drug called CHS-114 in people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein on certain immune cells to help the body fight cancer. About 87 adults will take part to find safe doses and…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control

Last updated Jun 16, 2026 12:53 UTC

New hope for head and neck cancer: experimental drug faces final test

This study tests a new drug called petosemtamab against standard treatments in 600 people with advanced head and neck cancer that has spread or come back and cannot be cured. Participants must have already tried immunotherapy and chemotherapy. The goal is to see if petosemtamab h…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Merus B.V. • Aim: Disease control

Last updated Jun 16, 2026 12:53 UTC

New combo therapy aims to fight HPV head and neck cancer before standard treatment

This study tests a new drug called CUE-101, alone or with another drug (pembrolizumab), in 30 people with newly diagnosed HPV-16 positive head and neck cancer that cannot be easily removed with surgery. The goal is to see if these drugs can boost the immune system to fight the ca…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control

Last updated Jun 15, 2026 19:08 UTC

New immune drug AZD6750 targets Hard-to-Treat cancers

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jun 15, 2026 19:08 UTC

New drug duo aims to fight advanced head and neck cancer

This study tests two experimental drugs, SYS6010 and Enlonstobart, in people with head and neck cancer that has come back or spread. The goal is to see if the combination can shrink tumors and how safe it is. About 70 adults who have not had prior treatment for advanced disease w…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control

Last updated Jun 15, 2026 19:08 UTC

New radiation drug targets Hard-to-Treat cancers in first human trial

This early-phase study tests a new drug that delivers radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to other treatments. The main goals are to check safety and find the best dose. A…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jun 15, 2026 18:55 UTC

Engineered immune cells take on Hard-to-Treat cancers

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Anusha Kalbasi • Aim: Disease control

Last updated Jun 15, 2026 18:55 UTC

Could a Two-Drug punch before surgery shrink head & neck tumors?

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jun 12, 2026 12:08 UTC

New virus therapy takes on advanced cancers in first human trial

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Jun 12, 2026 12:06 UTC

Targeted radiation drug takes aim at Hard-to-Treat cancers

This early-phase study tests a new drug that delivers radiation directly to cancer cells in people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for early signs of …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 11, 2026 12:10 UTC

New combo therapy aims to boost survival in head and neck cancer

This study tests whether adding petosemtamab to the standard immunotherapy pembrolizumab helps people with advanced head and neck cancer live longer. About 700 adults with PD-L1 positive cancer that has spread or come back will receive either the combination or pembrolizumab alon…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Merus B.V. • Aim: Disease control

Last updated Jun 10, 2026 13:28 UTC

New hope for tough cancers: experimental drug DR-0202 enters human testing

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or prostate cancer) that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Dren Bio • Aim: Disease control

Last updated Jun 09, 2026 12:08 UTC

New drug duo aims to shrink head and neck tumors

This study tests whether a combination of two drugs, ACR-368 and low-dose gemcitabine, can shrink tumors or slow cancer growth in people with head and neck cancer that has come back or spread. About 43 adults will receive the drugs every two weeks. The goal is to see if the treat…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control

Last updated Jun 09, 2026 12:07 UTC

New pill takes on brain tumors and metastases in early trial

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control

Last updated Jun 08, 2026 13:05 UTC

New drug trial offers hope for Hard-to-Treat head and neck cancers

This early-phase study tests a new drug called BL-M24D1 in people with advanced head and neck cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 16 adults aged 18 to 75 will ta…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 08, 2026 13:03 UTC

Radioactive spy seeks out cancer in neck lymph nodes

This early-stage trial tests whether a radioactive imaging agent called 111In-panitumumab can help find cancer that has spread to lymph nodes in people with head and neck cancer. About 30 patients scheduled for surgery will receive the agent and undergo SPECT/CT scans. The goal i…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis

Last updated Jun 23, 2026 11:59 UTC

Glow stick for cancer: new dye helps surgeons spot hidden tumors

This study tests a dye called pegsitacianine that makes cancer cells glow during surgery. It is for 120 adults with head and neck cancer, including those with an unknown primary tumor. The goal is to see if the dye helps surgeons find and remove all cancer tissue safely.

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Diagnosis

Last updated Jun 22, 2026 12:05 UTC

New imaging combo could help surgeons spot hidden cancer during surgery

This early-phase trial is testing whether combining two imaging techniques can help surgeons find and remove head and neck cancer more completely. About 40 adults with head and neck cancer will receive a special radioactive dye before surgery, followed by a fluorescent dye during…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis

Last updated Jun 15, 2026 19:03 UTC

New scan could spot hidden cancer spread in head and neck patients

This study tests a new imaging agent called 89Zr panitumumab to see if it can more accurately find cancer that has spread in people with head and neck cancer. Standard PET/CT scans often miss or wrongly identify these spots. About 60 participants will receive the new agent and th…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Eben Rosenthal • Aim: Diagnosis

Last updated Jun 11, 2026 12:11 UTC

New PET tracer could slash unnecessary biopsies for head and neck cancer patients

Prevention Recruiting now

This early-phase study tests a new radioactive tracer called [18F]NOTA-ABY030, which is designed to make head and neck squamous cell carcinoma show up more clearly on PET/CT scans. About 25 adults with suspicious or unclear findings on standard scans will receive the tracer and b…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis

Last updated Jun 10, 2026 13:29 UTC

Ice microneedles aim to stop radiation skin damage in cancer patients

This early-stage study tests whether a protein called CFH, delivered through tiny ice microneedles, can prevent skin scarring caused by radiation therapy. Nine adults with head and neck cancer who will receive radiation after surgery are being enrolled. The main goals are to chec…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE1 • Sponsor: West China Hospital • Aim: Prevention

Last updated Jun 18, 2026 11:49 UTC

Could a common drug help cancer patients keep their appetite?

This phase 2 trial tests whether adding olanzapine to standard care helps manage appetite loss in head and neck cancer patients undergoing chemoradiation. About 66 adults will receive either olanzapine plus standard symptom management or standard care alone. The main goal is to s…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief

Last updated Jun 23, 2026 11:57 UTC

Can a fat flap reduce neck pain after cancer? small study aims to find out

This pilot study tests whether a buried fat flap surgery can safely reduce neck morbidity—like pain, stiffness, and swallowing trouble—in people treated for head and neck cancer. Twelve adults who need salvage neck dissection after radiation will receive the flap and be monitored…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief

Last updated Jun 22, 2026 11:57 UTC

Heat boost: new combo therapy aims to shrink incurable tumors

This study tests whether adding a special heat treatment (water-filtered infrared, or wIRA) to standard palliative radiation can help shrink tumors and ease symptoms in people with advanced head, neck, or skin cancer that cannot be cured. About 60 adults will receive the combined…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: King's College London • Aim: Symptom relief

Last updated Jun 16, 2026 12:49 UTC

Can a constipation drug help head and neck cancer patients before surgery?

This study tests whether a drug called methylnaltrexone is safe for people with head and neck cancer when taken for two weeks before their surgery. The drug is already used for constipation, but researchers want to see if it can be given safely in this setting. About 25 adults wi…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE4 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated Jun 15, 2026 19:03 UTC

New drug aims to prevent painful mouth sores in head and neck cancer treatment

This study tests whether adding BMX-001 to standard care can reduce severe mouth sores caused by chemoradiation in head and neck cancer patients. About 98 participants will receive either BMX-001 or a placebo alongside usual mouth rinses and pain medications. The goal is to impro…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief

Last updated Jun 15, 2026 18:57 UTC

Can a nutrition drink ease chemo side effects? new study aims to find out

This study tests whether a special nutrition supplement can reduce severe side effects from standard cancer treatments in people with head and neck, lung, or rectal cancer. About 52 participants will take the supplement during their treatment, and their results will be compared t…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Symptom relief

Last updated Jun 15, 2026 18:57 UTC

Shorter radiation may bring faster relief for head and neck cancer patients

This study tests whether a shorter course of high-precision radiation (SBRT) can safely reduce symptoms in people with head and neck cancer that cannot be cured. About 108 adults whose cancer has returned or spread will receive either standard or shorter radiation. The goal is to…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief

Last updated Jun 12, 2026 12:07 UTC

New hope for cancer patients: drug may replace opioids for mouth sore pain

This study tests whether a high dose of gabapentin, a non-opioid pain medicine, can prevent the need for opioid painkillers in people with head and neck cancer who develop painful mouth sores from chemotherapy and radiation. About 228 participants will be randomly assigned to rec…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief

Last updated Jun 11, 2026 12:09 UTC

Heavy lifting may help cancer survivors rebuild strength

This study tests whether a heavy lifting strength training program is safe and helpful for people who have finished treatment for head and neck cancer at least one year ago. Researchers want to see if it improves muscle strength, physical function, fatigue, and quality of life co…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Alberta • Aim: Symptom relief

Last updated Jun 08, 2026 13:05 UTC

Can MRI scans make radiation smarter for head and neck cancer?

This study is testing whether regular MRI scans during radiation therapy can help doctors see how tumors respond and where they are most aggressive. About 173 people with head and neck cancer, plus 20 healthy volunteers, will get extra MRI scans during their treatment. The goal i…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused

Last updated Jun 23, 2026 12:00 UTC

New antibody fragments light up tumors in early imaging trial

This early-phase trial is testing two new antibody fragments that are designed to attach to a sugar molecule found on many solid tumors. The fragments are labeled with a radioactive tracer so they can be seen on PET/CT scans. The study aims to see where these fragments go in the …

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: EARLY_PHASE1 • Sponsor: Var2 Pharmaceuticals • Aim: Knowledge-focused

Last updated Jun 23, 2026 11:54 UTC

Cancer nutrition study aims to improve treatment tolerance

This study observes how diet and body composition change in 110 adults with head/neck, lung, or rectal cancer during standard treatment. Researchers measure daily calorie intake, muscle mass, and grip strength over time. The goal is to gather data to later develop a special nutri…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Knowledge-focused

Last updated Jun 22, 2026 12:06 UTC

Blood test may spare throat cancer patients from unnecessary radiation

This study is testing whether a blood test that looks for leftover tumor DNA after surgery can help decide who truly needs radiation. People with HPV-related throat cancer often do well, but standard treatments can cause harsh side effects. The goal is to give radiation only to t…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused

Last updated Jun 22, 2026 11:59 UTC

Remote hearing tests could save cancer Patients' hearing

This study tests whether offering hearing tests close to home or remotely increases how many head and neck cancer patients get their hearing checked during treatment. Many patients on cisplatin chemotherapy or radiation near the ear can lose hearing, but not all complete recommen…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused

Last updated Jun 22, 2026 11:57 UTC

New imaging study aims to spot radiation damage to neck arteries

This study looks at how radiation therapy for head and neck cancers affects the blood vessels in the neck. Researchers will use two types of PET/CT scans to compare images taken before and after treatment. The goal is to better understand and detect radiation-related vascular dam…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: EARLY_PHASE1 • Sponsor: Emory University • Aim: Knowledge-focused

Last updated Jun 17, 2026 12:07 UTC

New program aims to speed up cancer treatment after surgery

This study tests a program called ENDURE that helps head and neck cancer patients start radiation therapy within 6 weeks after surgery, as guidelines recommend. About 532 adults with certain types of head and neck cancer will take part. The program uses patient navigators to guid…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Medical University of South Carolina • Aim: Knowledge-focused

Last updated Jun 16, 2026 12:49 UTC

Virtual reality could make head and neck cancer surgery more precise

This study explores whether virtual reality and 3D models can help surgeons plan head and neck cancer operations more accurately. About 160 adults with head and neck cancer will take part. The goal is to see if this technology reduces the chance of leftover cancer cells and impro…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Phase: NA • Sponsor: Thomas Jefferson University • Aim: Knowledge-focused

Last updated Jun 15, 2026 19:08 UTC

Mini-Tumors in a dish may guide cancer treatment choices

This study looks at whether tiny lab-grown copies of a patient's tumor (called organoids) can predict which drugs will work best for that person. Researchers will compare the organoid test results with how the patient actually responds to treatment. The goal is to see if this app…

Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA

Sponsor: Huashan Hospital • Aim: Knowledge-focused

Last updated Jun 15, 2026 19:04 UTC

Blood test and gene clues may predict throat cancer return